<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01464164</url>
  </required_header>
  <id_info>
    <org_study_id>11-02-199 - 06A</org_study_id>
    <nct_id>NCT01464164</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia</brief_title>
  <acronym>ACE-011-DBA</acronym>
  <official_title>Phase I/II, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults With Red Blood Cell Transfusion- Dependent Diamond Blackfan Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and dosing of drug Sotatercept, as a
      subcutaneous injection, to stimulate production of red blood cell production. To be given
      every 28 days for up to four doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is for adult patients with Diamond Blackfan Anemia who are currently being
      transfused every 3- 4 weeks.

      The drug will be given as a subcutaneous injection within one of three dose levels. The first
      dose level (0.1 mg/kg) will include 3 subjects who will receive the same dose of the drug
      monthly for a total of 4 doses, as long as there are no dose- limiting toxicities (DLTs). A
      Dose limiting toxicity is defined as inability to deliver the scheduled doses because of
      toxicity &gt;/= Grade 3, according to NCI Toxicity Grading Scale.

      Once all 3 subjects have received and tolerated the low dose level, the next level will open
      (0.3 mg/kg)to 3 new subjects. Subjects will be monitored closely for response and side
      effects.

      If more than 2 subjects have a dose limiting toxicity in the first dose level, then dose
      level -1 (0.05 mg/kg)will open, enrolling 3 more subjects. If more than 2 subjects at dose
      level -1, have dose limiting toxicities, the study will be discontinued. If there are no
      additional dose limiting toxicities, dose level -1 will be the maximum tolerated dose.

      There are a total of 3 dose levels, not including dose level -1. Once the maximum tolerated
      dose has been reached, up to a total of 10 additional subjects will be enrolled.

      Protocol Amendment: The protocol has been amended to include an additional enrollment of 20
      subjects with two additional dose levels of Sotatercept (0.075 mg/kg and 0.100 mg/kg ) to be
      given with or without a prednisone boost.

      Efficacy will be measured by response. A complete response will be determined if the subject
      no longer requires transfusion, while on study drug. A partial response will be measured by a
      reduction by 50% in need for transfusion.

      Treatment modifications will be made based on evidence of side effects. Dose- escalation will
      be performed only if no side effects are reported and no efficacy is evidenced. Treatment
      will be stopped if hemoglobin is &gt;12 gm/dl and/ or any &gt;/+ grade 3 adverse event is related
      to sotatercept.

      Study assessments will include:

        -  Physical exam (height, weight, vital signs and blood pressure)at screening, day 1 of
           each cycle and monthly for 3 months of follow up period as well as at study
           discontinuation.

        -  Additional blood pressure monitoring at day 1 of each cycle and weekly there after
           through cycle 4, monthly in follow up period and at study discontinuation.

        -  Karnofsky performance status at screening, day 1 of cycle 2 and day 1 of monthly follow
           up period for 3 months and study discontinuation.

        -  CBC reticulocyte count and ANC will be collected at day 1 of each cycle and weekly there
           after through cycle 4, monthly in follow up period and at study discontinuation.

        -  Blood chemistry, liver and kidney function will be assessed at screening, day 1 and 15
           of cycle 1, day 1 of cycle 2, 3, 4 month 1 in follow up and at study discontinuation.

        -  Blood for iron status (serum iron, transferrin and %, ferritin) will be collected during
           the screening period, and at month 1 of the follow-up period as well as study
           discontinuation.

        -  Folate and B12 levels will be assessed during the screening period at day 1 of cycle 3
           and again at study discontinuation.

        -  Urinalysis (creatinine, protein),at screening, day 15 of cycle 1, day 1 of cycles 2, 3,
           and 4 monthly during follow-up and at study discontinuation.

        -  Serum erythropoietin at screening, day 15 of cycle 1, day 1 of cycle 3, monthly during
           follow-up and at study discontinuation.

        -  FSH &amp; LH (everyone), DHEA &amp; testosterone (males only), estrogen &amp; estradiol (females
           only)at screening, day 1 of cycles 2, 3, and 4, monthly during follow- up period and at
           study discontinuation.

        -  EKG &amp; ECHO at screening, day 1 of cycle 3 first month of follow-up period and at study
           discontinuation

        -  Dexa Scan at screening, day 1 of monthly follow-up period and at study discontinuation

        -  Transfusion assessment at screening, day 1, 8, 15 and 22 of cycle 1, day 1 and 15 of
           cycles 2, 3, and 4, monthly during follow-up period and at study discontinuation.

        -  Response assessment at day 8, 15, 22 of cycle 1, day 1 and 15 of cycles2, 3, and 4,
           monthly for 3 months during follow-up period and at study discontinuation

        -  Adverse events, concomitant therapies to be assessed at day 1, 8, 15, and 22 of cycle 1,
           day 1 and 15 of cycles 2, 3, and 4, monthly during follow-up period and at study
           discontinuation

        -  Drug administration day 1 of cycles 1, 2, 3, and 4.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine a safe and effective dose of sotatercept in adults with DBA and RBC transfusion dependence</measure>
    <time_frame>9 months</time_frame>
    <description>Achieve a complete response transfusion- independent and Hemoglobin &gt;9 gm/dl or a partial response- increase in transfusion interval from baseline and hemoglobin &lt; 9gm/dl iith an increase in reticulocyte count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>9 months</time_frame>
    <description>Assess type, frequency, and severity of adverse events and relationship to sotatercept according to the currently active minor version of the NCI Common Terminology for Adverse Events version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>9 months</time_frame>
    <description>Length of time required to achieve a response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>9 months</time_frame>
    <description>Length of time between transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory outcome improvement of bone density</measure>
    <time_frame>9 months</time_frame>
    <description>Improvement as measured by bone densitometry (DEXA scan)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diamond Blackfan Anemia</condition>
  <arm_group>
    <arm_group_label>Sotatercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sotatercept to be given as a subcutaneous injection once a month for 4 consecutive months, using a dose escalation scale among 3 cohorts. *Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotatercept with prednisone boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocol Amendment: Two additional cohorts will be given Sotatercept 0.75mg/kg and 1 mg/kg as a subcutaneous injection once every 3 weeks along with a prednisone boost of 1 mg/kg daily for 3 weeks (max of 60 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotatercept</intervention_name>
    <description>Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:
Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks</description>
    <arm_group_label>Sotatercept</arm_group_label>
    <other_name>ACE-011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotatercept with prednisone boost</intervention_name>
    <description>Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:
Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg).</description>
    <arm_group_label>Sotatercept with prednisone boost</arm_group_label>
    <other_name>ACE-011 and Prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;/= 18 years of age

          -  DBA diagnosed

          -  RBC transfusion- dependence (defined as &gt;/= 10 cc/kg of RBC per 28 days average)

          -  Karnofsky performance scale &gt;/= 70

          -  Females of childbearing potential are to use birth control during study participation
             and for 112 days following the last dose of sotatercept

          -  Males must agree to use a latex condom during any sexual contact with females of
             childbearing potential while participating in the study and for 112 days following the
             last dose of sotatercept

          -  Agreement to adhere to the study visit schedule, understand and comply with all
             protocol requirements

          -  Understand and sign a written informed consent

        Exclusion Criteria:

          -  Creatinine clearance &lt; 30 ml/min

          -  SGOT &gt; 3x upper limit of normal, SGPT &gt; 3x upper limit normal, or bilirubin &gt;3x upper
             limit normal

          -  Heart disease (NY Heart Association classification of &gt;/= 3

          -  History of hypertension

          -  Subjects currently responsive to corticosteroids for treatment of Diamond Blackfan
             anemia

          -  Treatment with another investigational drug or device &lt;56 days pre-study entry

          -  Pregnant or lactating females

          -  Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrianna Vlachos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health/Feinstein Institute for Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johnson Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health/Feinstein Institute for Medical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Atsidaftos, MA, CCRC</last_name>
    <phone>516-562-1504</phone>
    <email>eatsidaf@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chelsye Nelson, BA</last_name>
    <phone>516-562-1505</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>North Shore- LIJ campus of The Feinstein Institute for Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Atsidaftos, MA</last_name>
      <phone>516-562-1504</phone>
      <email>eatsidaf@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Adrianna Vlachos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johnson Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffrey M Lipton, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abkowitz JL, Schaison G, Boulad F, Brown DL, Buchanan GR, Johnson CA, Murray JC, Sabo KM. Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis. Blood. 2002 Oct 15;100(8):2687-91.</citation>
    <PMID>12351372</PMID>
  </reference>
  <reference>
    <citation>Diamond LK, Wang WC, Alter BP. Congenital hypoplastic anemia. Adv Pediatr. 1976;22:349-78. Review.</citation>
    <PMID>773132</PMID>
  </reference>
  <reference>
    <citation>Ball SE, McGuckin CP, Jenkins G, Gordon-Smith EC. Diamond-Blackfan anaemia in the U.K.: analysis of 80 cases from a 20-year birth cohort. Br J Haematol. 1996 Sep;94(4):645-53.</citation>
    <PMID>8826887</PMID>
  </reference>
  <reference>
    <citation>Bastion Y, Bordigoni P, Debré M, Girault D, Leblanc T, Tchernia G, Ball S, McGuckin C, Gordon-Smith EC, Békassy A, et al. Sustained response after recombinant interleukin-3 in diamond blackfan anemia. Blood. 1994 Jan 15;83(2):617-8.</citation>
    <PMID>8286756</PMID>
  </reference>
  <reference>
    <citation>Cmejla R, Cmejlova J, Handrkova H, Petrak J, Pospisilova D. Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia. Hum Mutat. 2007 Dec;28(12):1178-82.</citation>
    <PMID>17647292</PMID>
  </reference>
  <reference>
    <citation>Da Costa L, Moniz H, Simansour M, Tchernia G, Mohandas N, Leblanc T. Diamond-Blackfan anemia, ribosome and erythropoiesis. Transfus Clin Biol. 2010 Sep;17(3):112-9. doi: 10.1016/j.tracli.2010.06.001. Epub 2010 Jul 23.</citation>
    <PMID>20655265</PMID>
  </reference>
  <reference>
    <citation>Doherty L, Sheen MR, Vlachos A, Choesmel V, O'Donohue MF, Clinton C, Schneider HE, Sieff CA, Newburger PE, Ball SE, Niewiadomska E, Matysiak M, Glader B, Arceci RJ, Farrar JE, Atsidaftos E, Lipton JM, Gleizes PE, Gazda HT. Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2010 Feb 12;86(2):222-8. doi: 10.1016/j.ajhg.2009.12.015. Epub 2010 Jan 28. Erratum in: Am J Hum Genet. 2010 Apr 9;86(4):655.</citation>
    <PMID>20116044</PMID>
  </reference>
  <reference>
    <citation>Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, Ball S, Tchernia G, Klar J, Matsson H, Tentler D, Mohandas N, Carlsson B, Dahl N. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999 Feb;21(2):169-75.</citation>
    <PMID>9988267</PMID>
  </reference>
  <reference>
    <citation>Farrar JE, Nater M, Caywood E, McDevitt MA, Kowalski J, Takemoto CM, Talbot CC Jr, Meltzer P, Esposito D, Beggs AH, Schneider HE, Grabowska A, Ball SE, Niewiadomska E, Sieff CA, Vlachos A, Atsidaftos E, Ellis SR, Lipton JM, Gazda HT, Arceci RJ. Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood. 2008 Sep 1;112(5):1582-92. doi: 10.1182/blood-2008-02-140012. Epub 2008 Jun 5.</citation>
    <PMID>18535205</PMID>
  </reference>
  <reference>
    <citation>Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. What are RBC-transfusion-dependence and -independence? Leuk Res. 2011 Jan;35(1):8-11. doi: 10.1016/j.leukres.2010.07.015. Epub 2010 Aug 7.</citation>
    <PMID>20692036</PMID>
  </reference>
  <reference>
    <citation>Gazda HT, Grabowska A, Merida-Long LB, Latawiec E, Schneider HE, Lipton JM, Vlachos A, Atsidaftos E, Ball SE, Orfali KA, Niewiadomska E, Da Costa L, Tchernia G, Niemeyer C, Meerpohl JJ, Stahl J, Schratt G, Glader B, Backer K, Wong C, Nathan DG, Beggs AH, Sieff CA. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2006 Dec;79(6):1110-8. Epub 2006 Nov 2.</citation>
    <PMID>17186470</PMID>
  </reference>
  <reference>
    <citation>Gazda HT, Sheen MR, Vlachos A, Choesmel V, O'Donohue MF, Schneider H, Darras N, Hasman C, Sieff CA, Newburger PE, Ball SE, Niewiadomska E, Matysiak M, Zaucha JM, Glader B, Niemeyer C, Meerpohl JJ, Atsidaftos E, Lipton JM, Gleizes PE, Beggs AH. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet. 2008 Dec;83(6):769-80. doi: 10.1016/j.ajhg.2008.11.004.</citation>
    <PMID>19061985</PMID>
  </reference>
  <reference>
    <citation>Glader BE, Backer K, Diamond LK. Elevated erythrocyte adenosine deaminase activity in congenital hypoplastic anemia. N Engl J Med. 1983 Dec 15;309(24):1486-90.</citation>
    <PMID>6646173</PMID>
  </reference>
  <reference>
    <citation>Gustavsson P, Skeppner G, Johansson B, Berg T, Gordon L, Kreuger A, Dahl N. Diamond-Blackfan anaemia in a girl with a de novo balanced reciprocal X;19 translocation. J Med Genet. 1997 Sep;34(9):779-82.</citation>
    <PMID>9321770</PMID>
  </reference>
  <reference>
    <citation>Leblanc TM, Da Costa L, Marie I, Demolis P, Tchernia G. Metoclopramide treatment in DBA patients: no complete response in a French prospective study. Blood. 2007 Mar 1;109(5):2266-7.</citation>
    <PMID>17312003</PMID>
  </reference>
  <reference>
    <citation>Lipton JM, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer. 2006 May 1;46(5):558-64.</citation>
    <PMID>16317735</PMID>
  </reference>
  <reference>
    <citation>Lipton JM, Kudisch M, Gross R, Nathan DG. Defective erythroid progenitor differentiation system in congenital hypoplastic (Diamond-Blackfan) anemia. Blood. 1986 Apr;67(4):962-8.</citation>
    <PMID>3955239</PMID>
  </reference>
  <reference>
    <citation>Liu JM, Ellis SR. Ribosomes and marrow failure: coincidental association or molecular paradigm? Blood. 2006 Jun 15;107(12):4583-8. Epub 2006 Feb 28. Review.</citation>
    <PMID>16507776</PMID>
  </reference>
  <reference>
    <citation>Murata M, Onomichi K, Eto Y, Shibai H, Muramatsu M. Expression of erythroid differentiation factor (EDF) in Chinese hamster ovary cells. Biochem Biophys Res Commun. 1988 Feb 29;151(1):230-5.</citation>
    <PMID>3348775</PMID>
  </reference>
  <reference>
    <citation>Narla A, Vlachos A, Nathan DG. Diamond Blackfan anemia treatment: past, present, and future. Semin Hematol. 2011 Apr;48(2):117-23. doi: 10.1053/j.seminhematol.2011.01.004. Review.</citation>
    <PMID>21435508</PMID>
  </reference>
  <reference>
    <citation>Nishiura H, Tanase S, Shibuya Y, Futa N, Sakamoto T, Higginbottom A, Monk P, Zwirner J, Yamamoto T. S19 ribosomal protein dimer augments metal-induced apoptosis in a mouse fibroblastic cell line by ligation of the C5a receptor. J Cell Biochem. 2005 Feb 15;94(3):540-53.</citation>
    <PMID>15543555</PMID>
  </reference>
  <reference>
    <citation>Ohene-Abuakwa Y, Orfali KA, Marius C, Ball SE. Two-phase culture in Diamond Blackfan anemia: localization of erythroid defect. Blood. 2005 Jan 15;105(2):838-46. Epub 2004 Jul 6.</citation>
    <PMID>15238419</PMID>
  </reference>
  <reference>
    <citation>Perrien DS, Akel NS, Edwards PK, Carver AA, Bendre MS, Swain FL, Skinner RA, Hogue WR, Nicks KM, Pierson TM, Suva LJ, Gaddy D. Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology. 2007 Apr;148(4):1654-65. Epub 2006 Dec 28.</citation>
    <PMID>17194739</PMID>
  </reference>
  <reference>
    <citation>Quarello P, Garelli E, Carando A, Brusco A, Calabrese R, Dufour C, Longoni D, Misuraca A, Vinti L, Aspesi A, Biondini L, Loreni F, Dianzani I, Ramenghi U. Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations. Haematologica. 2010 Feb;95(2):206-13. doi: 10.3324/haematol.2009.011783. Epub 2009 Sep 22.</citation>
    <PMID>19773262</PMID>
  </reference>
  <reference>
    <citation>Rivier J, Spiess J, McClintock R, Vaughan J, Vale W. Purification and partial characterization of inhibin from porcine follicular fluid. Biochem Biophys Res Commun. 1985 Nov 27;133(1):120-7.</citation>
    <PMID>4074357</PMID>
  </reference>
  <reference>
    <citation>Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, Seehra J, Yang Y, Condon CH, Sherman ML. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009 Apr;24(4):744-52. doi: 10.1359/jbmr.081208.</citation>
    <PMID>19049340</PMID>
  </reference>
  <reference>
    <citation>Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, Meerpohl J, Karlsson S, Liu JM, Leblanc T, Paley C, Kang EM, Leder EJ, Atsidaftos E, Shimamura A, Bessler M, Glader B, Lipton JM; Participants of Sixth Annual Daniella Maria Arturi International Consensus Conference. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008 Sep;142(6):859-76. doi: 10.1111/j.1365-2141.2008.07269.x. Epub 2008 Jul 30.</citation>
    <PMID>18671700</PMID>
  </reference>
  <reference>
    <citation>Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood. 2010 Nov 11;116(19):3715-23. doi: 10.1182/blood-2010-02-251090. Epub 2010 Jul 22. Review.</citation>
    <PMID>20651069</PMID>
  </reference>
  <reference>
    <citation>Vlachos A, Federman N, Reyes-Haley C, Abramson J, Lipton JM. Hematopoietic stem cell transplantation for Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Bone Marrow Transplant. 2001 Feb;27(4):381-6.</citation>
    <PMID>11313667</PMID>
  </reference>
  <reference>
    <citation>Vlachos A, Klein GW, Lipton JM. The Diamond Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond-Blackfan anemia. J Pediatr Hematol Oncol. 2001 Aug-Sep;23(6):377-82. Review.</citation>
    <PMID>11563775</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2011</study_first_submitted>
  <study_first_submitted_qc>November 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2011</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Adrianna Vlachos</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diamond Blackfan anemia</keyword>
  <keyword>DBA</keyword>
  <keyword>Blackfan Diamond anemia</keyword>
  <keyword>Congenital pure red cell aplasia</keyword>
  <keyword>Aase-Smith II Syndrome</keyword>
  <keyword>Aase Syndrome</keyword>
  <keyword>Anemia, Congenital Pure Red Cell</keyword>
  <keyword>Aplasia, Congenital Pure Red Cell</keyword>
  <keyword>BDA</keyword>
  <keyword>Congenital Hypoplastic Anemia</keyword>
  <keyword>Erythrogenesis Imperfecta</keyword>
  <keyword>Hypoplastic Congenital Anemia</keyword>
  <keyword>Inherited Erythroblastopenia</keyword>
  <keyword>pure red cell aplasia</keyword>
  <keyword>bone marrow failure syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Diamond-Blackfan</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

